We are live on
!
Find out more
RCM
RA Capital Management Portfolio holdings
AUM
$9.44B
1-Year Est. Return
157.3%
This Fund
S&P 500
This Quarter
Est. Return
+1.24%
1 Year Est. Return
+157.3%
3 Year Est. Return
+589.39%
5 Year Est. Return
+654.96%
10 Year Est. Return
+50,915.53%
AUM
$6.63B
AUM Growth
-$522M
(-7.3%)
Cap. Flow
-$72.7M
Cap. Flow
% of AUM
-1.1%
Top 10 Holdings %
Top 10 Hldgs %
50.25%
Holding
100
New
18
Increased
9
Reduced
13
Closed
18
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vor Biopharma
VOR
|
+$470M |
| 2 |
Instil Bio
TIL
|
+$125M |
| 3 |
Seres Therapeutics
MCRB
|
+$85.1M |
| 4 |
Edgewise Therapeutics
EWTX
|
+$84.8M |
| 5 |
Ascendis Pharma A/S
ASND
|
+$83.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Arvinas
ARVN
|
+$312M |
| 2 |
TG Therapeutics
TGTX
|
+$195M |
| 3 |
Novavax
NVAX
|
+$157M |
| 4 |
Keros Therapeutics
KROS
|
+$132M |
| 5 |
CCXI
ChemoCentryx, Inc.
CCXI
|
+$73.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 95.53% |
| 2 | Financials | 0.47% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Ascendis Pharma A/S
ASND
$16.5B
| $826M | 12.46% |
6,412,228
+546,890
| +9% | +$83.1M |
|
|
2
Novavax
NVAX
$1.21B
| $544M | 8.21% |
3,002,087
-786,477
| -21% | -$157M |
|
|
3
Vor Biopharma
VOR
$1.06B
| $479M | 7.23% |
+556,049
| New | +$470M |
|
4
Atea Pharmaceuticals
AVIR
$370M
| $332M | 5% |
5,368,451
| – | – |
|
|
FMTX
5
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
| $253M | 3.81% |
9,011,651
| – | – |
|
|
6
TG Therapeutics
TGTX
$8.19B
| $223M | 3.37% |
4,636,146
-4,049,325
| -47% | -$195M |
|
7
Nkarta
NKTX
$152M
| $184M | 2.78% |
5,605,129
| – | – |
|
|
CCXI
8
DELISTED
ChemoCentryx, Inc.
CCXI
| $182M | 2.75% |
3,556,810
-1,219,738
| -26% | -$73.4M |
|
9
MacroGenics
MGNX
$233M
| $157M | 2.37% |
4,933,594
+558,377
| +13% | +$13.6M |
|
|
ITOS
10
DELISTED
iTeos Therapeutics
ITOS
| $151M | 2.28% |
4,417,258
| – | – |
|
|
IMGN
11
DELISTED
Immunogen Inc
IMGN
| $149M | 2.25% |
18,417,458
| – | – |
|
12
Travere Therapeutics
TVTX
$5.17B
| $140M | 2.11% |
5,614,428
+1,056,561
| +23% | +$29.2M |
|
|
13
Instil Bio
TIL
$49M
| $122M | 1.84% |
+243,540
| New | +$125M |
|
14
Phathom Pharmaceuticals
PHAT
$928M
| $117M | 1.76% |
3,115,008
-710,000
| -19% | -$29.7M |
|
|
ETNB
15
DELISTED
89bio
ETNB
| $112M | 1.69% |
4,736,214
| – | – |
|
|
KNTE
16
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
| $112M | 1.69% |
3,593,052
| – | – |
|
17
Rhythm Pharmaceuticals
RYTM
$7.31B
| $104M | 1.56% |
4,871,067
+692,000
| +17% | +$20.1M |
|
|
ZGNX
18
DELISTED
Zogenix, Inc.
ZGNX
| $103M | 1.56% |
5,283,976
-61,655
| -1% | -$1.26M |
|
19
Axsome Therapeutics
AXSM
$11.7B
| $93.7M | 1.41% |
1,655,447
| – | – |
|
20
Rocket Pharmaceuticals
RCKT
$343M
| $93.5M | 1.41% |
2,107,149
-28,932
| -1% | -$1.59M |
|
|
ADVM
21
DELISTED
Adverum Biotechnologies
ADVM
| $92.3M | 1.39% |
936,583
-13,655
| -1% | -$1.64M |
|
|
22
Edgewise Therapeutics
EWTX
$4.28B
| $84.9M | 1.28% |
+2,613,623
| New | +$84.8M |
|
23
Curis
CRIS
$9.71M
| $80.8M | 1.22% |
17,850
-1,419
| -7% | -$5.93M |
|
24
Bolt Biotherapeutics
BOLT
$7.4M
| $78.3M | 1.18% |
+118,916
| New | +$77.4M |
|
25
Vaxcyte
PCVX
$7.65B
| $76.3M | 1.15% |
3,865,808
+155,109
| +4% | +$3.9M |
|
Similar funds
RCMNY
SCM
SIM
NPT
AC
PVI
WPL
BAMF
RA Capital Management's Q1 2021 Portfolio in Review
As of Q1 2021, RA Capital Management held 100 positions worth $6.63B, down 7.3% from $7.15B the previous quarter. Its ten largest holdings account for 50% of the portfolio.
RA Capital Management's Q1 2021 filing shows 18 new, 9 increased, 13 reduced and 18 closed positions. Its largest new stake was Vor Biopharma: 556,049 shares worth $479M. The largest sale was Arvinas, an estimated $312M.
By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 94% a quarter earlier, followed by Financials.
- RA Capital Management's largest Q1 2021 buy was Vor Biopharma: 556,049 shares worth $479M.
- RA Capital Management added most to Ascendis Pharma A/S in Q1 2021, an estimated $83.1M increase.
- RA Capital Management's biggest Q1 2021 reduction was TG Therapeutics, cutting an estimated $195M.
- RA Capital Management fully exited Arvinas in Q1 2021, selling an estimated $312M.
- RA Capital Management's ten largest holdings make up 50% of its $6.63B portfolio in Q1 2021.
- RA Capital Management opened 18 new positions and closed 18 in Q1 2021.
- RA Capital Management's portfolio value fell 7.3% quarter-over-quarter to $6.63B.
Based on RA Capital Management's 13F filing for Q1 2021, filed 17 May 2021.